This article has Open Peer Review reports available.
Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes
© Ergul et al.; licensee BioMed Central Ltd. 2007
Received: 16 January 2007
Accepted: 15 October 2007
Published: 15 October 2007
Interruption of flow through of cerebral blood vessels results in acute ischemic stroke. Subsequent breakdown of the blood brain barrier increases cerebral injury by the development of vasogenic edema and secondary hemorrhage known as hemorrhagic transformation (HT). Diabetes is a risk factor for stroke as well as poor outcome of stroke. The current study tested the hypothesis that diabetes-induced changes in the cerebral vasculature increase the risk of HT and augment ischemic injury.
Diabetic Goto-Kakizaki (GK) or control rats underwent 3 hours of middle cerebral artery occlusion and 21 h reperfusion followed by evaluation of infarct size, hemorrhage and neurological outcome.
Infarct size was significantly smaller in GK rats (10 ± 2 vs 30 ± 4%, p < 0.001). There was significantly more frequent hematoma formation in the ischemic hemisphere in GK rats as opposed to controls. Cerebrovascular tortuosity index was increased in the GK model (1.13 ± 0.01 vs 1.34 ± 0.06, P < 0.001) indicative of changes in vessel architecture.
These findings provide evidence that there is cerebrovascular remodeling in diabetes. While diabetes-induced remodeling appears to prevent infarct expansion, these changes in blood vessels increase the risk for HT possibly exacerbating neurovascular damage due to cerebral ischemia/reperfusion in diabetes.
Ischemic stroke is a leading cause of death and disability in the United States and diabetes is the most rapidly increasing risk factor for stroke. Among patients with recent stroke, 70% have overt diabetes or prediabetes characterized by impaired fasting glucose or impaired glucose tolerance . Type 2 diabetes, a disease that affects more than 17 million Americans with an alarming number of new cases, holds a 2–6 fold increased risk for stroke. Not only is the incidence of stroke increased among diabetics, but stroke patients with diabetes have a worse outcome. Mortality is increased in diabetics at one week, one month and three months after stroke, and diabetic stroke survivors have more profound neurologic deficits and disability . In addition, diabetes and hyperglycemia predict early neurologic deterioration following ischemic stroke . A recent study reported that persistent post-stroke hyperglycemia causes infarct expansion and worse clinical outcome . Vascular complications of diabetes characterized by vascular dysfunction and pathological remodeling contribute to increased cardiovascular mortality and morbidity in diabetes, yet, changes in the cerebrovascular structure remain unknown.
During focal cerebral ischemia, damage to cerebral blood vessels occurs early and in a progressive fashion . Reperfusion through damaged cerebral blood vessels is likely to further increase the ultimate tissue damage due to ischemic stroke. If ischemia is prolonged, cerebral edema occurs and bleeding into the brain parenchyma known as hemorrhagic transformation (HT) ensues and worsens stroke outcome. In experimental transient middle cerebral artery occlusion (MCAO) models, acute hyperglycemia induced by glucose administration augments ischemic injury and increases HT [6–8]. However, the impact of chronic mild hyperglycemia as seen in majority of Type 2 diabetic patients on cerebral vessel structure and mechanisms and functional consequences especially in the acute ischemia/reperfusion injury setting are unclear. The current study tested the hypothesis that diabetes-induced changes in the cerebral vasculature increase the risk of HT and augment ischemic injury.
Animal and tissue preparation
GK rats, a spontaneous model of Type2 diabetes generated from selective inbreeding of glucose-intolerant Wistar rats, developed hyperglycemia at 6-weeks of age and had been diabetic for almost 4–5 weeks prior to stroke surgery. Regular Wistar rats served as control as reported . All experiments were performed on male Wistar (Harlan, Indianapolis, IN) and Goto-Kakizaki (in-house bred, derived from the Tampa colony) rats (n = 5–6/group) within a narrow range of body weight (250–290 g) . All protocols were approved by the Institutional Animal Care and Use Committee at the VA Medical Center. Animals were allowed access to food and water ad libitum, and were maintained on a 12/12 hour light/dark cycle. During housing, drinking water measurements, weight, and blood glucose measurements were performed twice weekly. Glucose measurements were taken from the tail vein and measured on a commercially available glucose meter (AccuChek, Roche Diagnostics, Indianapolis, IN) .
Experimental cerebral ischemia
All animals were anesthetized with 2% isoflurane via inhalation. Focal cerebral ischemia was induced using the intraluminal suture MCAO model as previously reported by us and others [11–13]. The right MCA was occluded with a 19–21 mm 3-0 surgical nylon filament, which was introduced from the external carotid artery lumen into the internal carotid artery to block the origin of the MCA. A significant drop in blood flow as measured by laser Doppler (Perimed, North Royalton, OH) indicated successful occlusion of the MCA. A similar degree of reduction in blood flow was achieved in both control and GK rats. The suture was removed after 3 hours of occlusion and measurement of blood flow was repeated to determine whether the flow was restored after reperfusion which appeared to be similar in both groups. The animals were then returned to their cages.
Neurologic function was quantified prior to reperfusion and at 24 hours (just prior to sacrifice) using the Bederson score [11, 12]. An animal with no apparent deficits obtains a 0 on the assessment and a score of 3 is consistent with a middle cerebral artery occlusion. Only animals with a score of 3 prior to reperfusion were included in the analysis.
Assessment of infarct size and hemorrhage
At 24 hours after the onset of MCAO, blood glucose was measured and then the animals were anesthetized with ketamine 44 mg/kg and xylazine 13 mg/kg I.M. (cocktail), perfused with saline, sacrificed and brains were removed. The brain tissue was sliced into seven 2-mm thick slices in the coronal plane. HT was defined as the presence of visible bleeding in coronal brain sections prior to staining. Slices were then stained with a 2% solution of 2, 3, 5-triphenyltetrazolium chloride (TTC) (Sigma Chemical Co., USA) for 15–20 minutes. Images of the stained sections were taken. Grossly visible infarction zones were quantified using image analysis software (Zeiss-KS300) [11–13]. The infarct volume was determined as % the contralateral hemisphere to correct for edema.
Visualization of cerebrovasculature and measurement of tortuosity index
Additional control and GK animals (250–290 g, n = 5/group) were anesthetized with sodium pentobarbital and injected with 40 mg/kg papaverine hydrochloride to induce maximal vasodilatation as previously described . The thoracic aorta was clipped and 2 ml of warm (37°C) latex (Vultex, Chicago Latex Products No. 563) mixed with carbon black was injected through the cannula over a 2-minute period. 15 minutes after the injection, rats were decapitated, brains were removed and placed in cold saline. Images of the top and bottom of the brains were digitized, divided into 6 regions with a grid and in each section 2 middle size vessels were traced on a Wacom tablet 493-3 using Image J I-36 software. Tortuosity index (TI) was defined as the ratio of the vessel length over straight line distance between two vessel ends. Then the average of 24 measurements was used as the TI per animal.
MCAs were perfused with Histogel (Richard Allen Scientific, Kalamazoo, MI), then excised and embedded in the same matrix. Upon gelling of the matrix, the embedded vessel was placed in 10% formalin, embedded in paraffin, sectioned at 4 microns and mounted on treated slides. Sections were stained with Masson trichrome stain. Slides were viewed using a Zeiss Axiovert microscope (Carl Zeiss, Inc., Thornwood, NY) and media:lumen ratios (M/L) were analyzed using Spot software (Diagnostic Instruments, MI). 4 measurements were made per section and each animal had at least 3 sections as we reported previously .
MCAs were homogenized and processed for MMP activity by gelatin zymography as we previously reported . Recombinant MMP-2 protein (Calbiochem, San Diego, CA) was run in parallel with all samples and the band intensity on zymogram gels was normalized to that of standard to prevent gel-to-gel variability. Gelatinolytic activity was assessed by densitometric analysis (Gel-Pro version 3.1, Media Cybernetics, Carlsbad, CA)
Comparisons of tortuosity index and infarct size between the two groups of rats were made using nonparametric Student's t-test. HT was analyzed by Fisher's exact test. Results are expressed as mean ± SEM. Effects were considered statistically significant at p < 0.05.
This study questioned whether and to what extent diabetes-induced changes in the cerebral vasculature increase the risk of hemorrhage and augment ischemic injury. There were 3 important findings in this study. First, infarct size was smaller and localization was different in the diabetic rats. Second, hemorrhagic transformation was increased in this group. Third, despite a very short duration of mild diabetes, tortuosity of cerebral vessels was significantly enhanced. These results provide important and timely information regarding the potential mechanisms that may contribute to increased stroke risk and worse outcome in diabetes.
In recent years, the role of hyperglycemia in the pathophysiology and outcome of acute ischemic stroke has gained significant attention. Numerous studies including the NINDS tPA stroke trial showed that elevated admission blood sugar was a significant predictor of poor clinical outcome and HT [16–18]. The relative role of acute versus chronic hyperglycemia in the pathogenesis of this poor outcome has been debated and has not been determined unequivocally . However, based on the findings that short-term mortality is higher and final infarct size is larger in nondiabetic patients who present with hyperglycemia at admission, several studies have suggested that hyperglycemia and not necessarily diabetes aggravates ischemic injury and stroke outcome [18, 19]. In experimental models, hyperglycemia has been shown to increase infarct size and a limited number of studies also demonstrated augmented HT in hyperglycemic ischemia/reperfusion injury [6–8]. However, these studies employed hyperglycemia induced by glucose injection prior to or at the time of MCA and blood glucose levels were above 300 mg/dl. The intriguing finding of the current study is that infarct size is smaller but secondary hemorrhage is larger in diabetic GK rats that present with moderate elevations in blood glucose (180–250 mg/dl). Consistent with smaller infarct size, diabetic rats had less edema. Moreover, the infarct is subcortical as opposed to subcortical and cortical localization in control rats. These results suggest a difference in the pathophysiology of ischemic injury in the diabetic state. It is well established that diabetes promotes ischemic preconditioning in the myocardium . It is also known that ischemic preconditioning is neuroprotective [21, 22]. It is possible that in our model, diabetes induced-changes in the cerebrovasculature result in ischemic preconditioning and thereby prevent infarct expansion but promote BBB breakdown and hemorrhage emphasizing the importance of the neurovascular unit.
During focal cerebral ischemia, disruption of the BBB complex, which consists of the endothelial cell, its tight junctions, the basal lamina and the astrocytic foot processes results in damage to the entire neurovascular unit [23–25]. If the ischemia is prolonged, breakdown of BBB increases cerebral injury by the development of vasogenic edema and secondary hemorrhage known as HT [11, 26]. Matrix metalloproteinases (MMPs) are a class of zinc-dependent endopeptidases that contribute to the breakdown of BBB. Several laboratories have demonstrated that MMP activity, especially gelatinases MMP-2 and MMP-9, is increased after focal cerebral ischemia and contributes to the development of HT [23, 25, 27, 28]. MMPs are also up-regulated in diabetes. We have also found that MMP activity is increased in MCAs of GK rats and this increase is associated with enhanced pathological remodeling after 10–12 weeks of diabetes . The animals used in the current study had mild diabetes only for 4–5 weeks. While we cannot rule out the possibility that in-breeding may cause alterations in vessel structure, reactivity and mechanics that may contribute to the changes we observe in this colony of diabetic rats, our data provide evidence that despite the short duration of diabetes, there was increased MMP-2 activity and tortuosity suggesting early cerebrovascular remodeling. This remodeling response may contribute to increased hemorrhage in diabetes.
Increased tortuosity is commonly measured in evaluation of coronary vessels. This is an indicator of ischemia-induced vascular restructuring as it increases vessel surface area. The current study found that the TI of cerebral vessels was increased in diabetes. These findings suggest that there is microvascular remodeling and potential neovascularization in the GK rat, which may contribute to decreased infarct size. Neovascularization in diabetes is very complex and regulated in a temporal and tissue specific manner. It is well established that hyperglycemia-mediated oxidative damage to microvascular endothelial cells triggers a cascade of events that lead to changes in vascular proliferative retinopathy and formation of new blood vessels on the surface of the retina [29, 30]. These immature vessels then break and leak worsening the retinal damage. Although we do not have direct evidence, it is highly possible that similar to retina, in the cerebrovasculature newly formed or remodeled vessels cannot resist the impact of ischemia/reperfusion injury and increased bleeding occurs. Preliminary evaluation of baseline BBB permeability in the absence of ischemic injury by Evans blue extravasation method was not sensitive to detect permeability differences between control and diabetic animals. Interestingly, edema after MCAO was significantly less in GK rats most likely due to smaller infarct size. It has to be recognized that the current study has several limitations. First, cerebral blood flow was measured to ensure that similar degree of blood flow is achieved in control versus diabetic rats during MCAO and after reperfusion but evaluation of blood flow with more reliable methods are needed to assess whether changes observed in vessel structure are associated with alterations in baseline blood flow as well as collateral flow during MCAO. Second, HT was defined as the presence of visible bleeding in coronal brain sections and more quantitative methods are needed. Similarly, vascular remodeling was assessed by visualization of the vascular tree, measurement of tortuosity and morphometry of histogel and not pressure-fixed vessels. Whether increased tortuosity is due to remodeling of existing vessels or due to neovascularization or both remains to be determined. Lastly, the effect(s) glycemic control on the severity of ischemic injury and outcome remain to be determined. Nevertheless our findings are very important and timely.
Given that thrombolytic therapy to open the occluded artery is the best chance to recover from ischemic damage and that admission blood glucose levels predict whether HT will complicate the thrombolytic therapy, better understanding of the mechanisms underlying increased bleeding in diabetes will identify novel therapeutic targets and strategies. The results of this study suggest that different mechanisms may contribute to ischemic damage in hyperglycemia versus diabetes.
This study is supported by research awards by Philip Morris USA Inc. and Philip Morris International, and NIH (R15HL76236, RO1 DK074385, RO3 NS054688) to AE and NIH (RO1NS044216) to SCF. SCF received a research grant from Pfizer, Inc.
- Kernan WN, Inzucchi SE: Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. Curr Treat Options Neurol. 2004, 6 (6): 443-450. 10.1007/s11940-004-0002-y.View ArticlePubMedGoogle Scholar
- Kaarisalo MM, Raiha I, Sivenius J, Immonen-Raiha P, Lehtonen A, Sarti C, Mahonen M, Torppa J, Tuomilehto J, Salomaa V: Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract. 2005, 69 (3): 293-298. 10.1016/j.diabres.2005.02.001.View ArticlePubMedGoogle Scholar
- Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC: Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol. 2005, 62 (3): 393-397. 10.1001/archneur.62.3.393.View ArticlePubMedGoogle Scholar
- Baird TA, Parsons MW, Phanh T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM: Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003, 34 (9): 2208-2214. 10.1161/01.STR.0000085087.41330.FF.View ArticlePubMedGoogle Scholar
- Cipolla MJ, McCall AL, Lessov N, Porter JM: Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke. 1997, 28 (1): 176-180.View ArticlePubMedGoogle Scholar
- de Courten-Myers GM, Kleinholz M, Holm P, DeVoe G, Schmitt G, Wagner KR, Myers RE: Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med. 1992, 21 (2): 120-126. 10.1016/S0196-0644(05)80144-1.View ArticlePubMedGoogle Scholar
- Kawai N, Keep RF, Betz AL: Hyperglycemia and the vascular effects of cerebral ischemia. Stroke. 1997, 28 (1): 149-154.View ArticlePubMedGoogle Scholar
- Venables GS, Miller SA, Gibson G, Hardy JA, Strong AJ: The effects of hyperglycaemia on changes during reperfusion following focal cerebral ischaemia in the cat. J Neurol Neurosurg Psychiatry. 1985, 48 (7): 663-669.View ArticlePubMedPubMed CentralGoogle Scholar
- Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, Fagan SC, Ergul A: Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes. 2005, 54 (9): 2638-2644. 10.2337/diabetes.54.9.2638.View ArticlePubMedGoogle Scholar
- Lindsberg PJ, Roine RO: Hyperglycemia in acute stroke. Stroke. 2004, 35 (2): 363-364. 10.1161/01.STR.0000115297.92132.84.View ArticlePubMedGoogle Scholar
- Fagan SC, Garcia JH: Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator. Pharmacotherapy. 1999, 19 (2): 139-142. 10.1592/phco.22.214.171.124932.View ArticlePubMedGoogle Scholar
- Harris AK, Ergul A, Kozak A, Machado LS, Johnson MH, Fagan SC: Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci. 2005, 6: 49-10.1186/1471-2202-6-49.View ArticlePubMedPubMed CentralGoogle Scholar
- Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC: Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens. 2006, 24 (3): 535-539. 10.1097/01.hjh.0000209990.41304.43.View ArticlePubMedGoogle Scholar
- Maeda K, Hata R, Hossmann KA: Regional metabolic disturbances and cerebrovascular anatomy after permanent middle cerebral artery occlusion in C57black/6 and SV129 mice. Neurobiol Dis. 1999, 6 (2): 101-108. 10.1006/nbdi.1998.0235.View ArticlePubMedGoogle Scholar
- Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A: Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2005Google Scholar
- Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002, 59 (5): 669-674.View ArticlePubMedGoogle Scholar
- Bruno A, Biller J, Adams HP, Clarke WR, Woolson RF, Williams LS, Hansen MD: Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999, 52 (2): 280-284.View ArticlePubMedGoogle Scholar
- Martini SR, Kent TA: Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab. 2006Google Scholar
- Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001, 32 (10): 2426-2432. 10.1161/hs1001.096194.View ArticlePubMedGoogle Scholar
- Monteiro P, Goncalves L, Providencia LA: Diabetes and cardiovascular disease: the road to cardioprotection. Heart. 2005, 91 (12): 1621-1625. 10.1136/hrt.2005.063008.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang PL: Nitric oxide and cerebral ischemic preconditioning. Cell Calcium. 2004, 36 (3–4): 323-329. 10.1016/j.ceca.2004.02.007.View ArticlePubMedGoogle Scholar
- Schaller B, Graf R: Cerebral ischemic preconditioning. An experimental phenomenon or a clinical important entity of stroke prevention?. J Neurol. 2002, 249 (11): 1503-1511. 10.1007/s00415-002-0933-8.View ArticlePubMedGoogle Scholar
- del Zoppo GJ, Mabuchi T: Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003, 23 (8): 879-894. 10.1097/01.WCB.0000078322.96027.78.View ArticlePubMedGoogle Scholar
- del Zoppo GJ, von Kummer R, Hamann GF: Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998, 65 (1): 1-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A: Targets for vascular protection after acute ischemic stroke. Stroke. 2004, 35 (9): 2220-2225. 10.1161/01.STR.0000138023.60272.9e.View ArticlePubMedGoogle Scholar
- Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA: Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res. 2003, 25 (4): 377-382. 10.1179/016164103101201526.View ArticlePubMedGoogle Scholar
- Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone F: Matrix metalloproteinase expression increases after cerebral focal ischemia. Stroke. 1998, 29: 1020-1030.View ArticlePubMedGoogle Scholar
- Rosenberg GA, Estrada EY, Dencoff JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998, 29 (10): 2189-2195.View ArticlePubMedGoogle Scholar
- Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005, 6 (4): 511-524. 10.2174/1389450054021981.View ArticlePubMedGoogle Scholar
- Silvestre JS, Levy BI: Molecular basis of angiopathy in diabetes mellitus. Circ Res. 2006, 98 (1): 4-6. 10.1161/01.RES.0000200396.90220.41.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/7/33/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.